MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 314272 | Name: Solithromycin
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Solithromycin, also known as CEM-101 and OP-1068, is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections. It is expected to be the first macrolide antibiotic available in intravenous, oral, and pediatric suspension formulations in over 20 years. Solithromycin exhibits excellent in vitro activity against a broad spectrum of Gram-positive respiratory tract pathogens, including macrolide-resistant strains. Solithromycin has activity against a wide variety of pathogens, and further research is being conducted for other infections.

Chemical Structure

Solithromycin
CAS#760981-83-7

Theoretical Analysis

MedKoo Cat#: 314272

Name: Solithromycin

CAS#: 760981-83-7

Chemical Formula: C43H65FN6O10

Exact Mass: 844.4746

Molecular Weight: 845.01

Elemental Analysis: C, 61.12; H, 7.75; F, 2.25; N, 9.95; O, 18.93

Price and Availability

Size Price Availability Quantity
10mg USD 135.00 Ready to Ship
25mg USD 210.00 Ready to ship
50mg USD 350.00 Ready to ship
100mg USD 550.00 Ready to ship
200mg USD 950.00 Ready to ship
1g USD 3,450.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
CEM101; CEM101; CEM 101; OP1068; OP1068; OP 1068; Solithromycin
IUPAC/Chemical Name
(3aS,4R,7R,9R,10R,11R,13R,15S,15aR)-1-(4-(4-(3-aminophenyl)-1H-1,2,3-triazol-1-yl)butyl)-10-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-ethyl-7-fluoro-11-methoxy-3a,7,9,11,13,15-hexamethyloctahydro-1H-[1]oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(7H,9H)-tetraone
InChi Key
IXXFZUPTQVDPPK-QIFQIIIXSA-N
InChi Code
InChI=1S/C43H65FN6O10/c1-12-32-43(8)35(50(40(55)60-43)19-14-13-18-49-23-30(46-47-49)28-16-15-17-29(45)21-28)26(4)33(51)24(2)22-41(6,56-11)37(27(5)36(53)42(7,44)39(54)58-32)59-38-34(52)31(48(9)10)20-25(3)57-38/h15-17,21,23-27,31-32,34-35,37-38,52H,12-14,18-20,22,45H2,1-11H3/t24-,25-,26-,27+,31+,32-,34-,35-,37-,38+,41-,42-,43-/m1/s1
SMILES Code
CC[C@@H]1[C@]2(C)[C@H](N(CCCCN3C=C(C4=CC(N)=CC=C4)N=N3)C(O2)=O)[C@H](C)C([C@H](C)C[C@@](C)(OC)[C@H](O[C@H]5[C@H](O)[C@@H](N(C)C)C[C@@H](C)O5)[C@@H](C)C([C@@](C)(F)C(O1)=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO.
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
Solithromycin binds to the large 50S subunit of the ribosome, with IC50s of 7.5 ng/mL, 40 ng/mL, and 125 ng/mL for Streptococcus pneumonia, Staphylococcus aureus, and Haemophilus influenzae, respectively.
In vitro activity:
Solithromycin has therapeutic potential in managing group B streptococcus (GBS) infections, even in the presence of antibiotic resistance. Solithromycin demonstrated lower MIC50 and MIC90 values against erythromycin-susceptible strains compared to penicillin, a first-line agent for GBS infections. Against erythromycin-resistant strains, solithromycin showed a MIC50 of 0.03 µg/ml and a MIC90 of 0.125 µg/ml, with a comparable MIC50 to penicillin (0.032 µg/ml) and a 2.7-fold lower MIC90 than solithromycin. Reference: Antimicrob Agents Chemother. 2014 Mar; 58(3): 1693–1698. https://pubmed.ncbi.nlm.nih.gov/24379197/
In vivo activity:
Solithromycin has therapeutic potential in the treatment of bacterial ear infections. This study tested solithromycin treatment in a chinchilla model of bacterial ear infections. For ear infections caused by NTHi, solithromycin successfully cleared the infection in over 85% of cases when the bacteria were susceptible to the drug. For infections caused by S. pneumoniae, solithromycin completely cleared the infection when the bacteria were susceptible to the drug, but some infection persisted when resistance was higher. Reference: Antimicrob Agents Chemother. 2016 Sep; 60(9): 5533–5538. https://pubmed.ncbi.nlm.nih.gov/27401563/
Solvent mg/mL mM comments
Solubility
DMSO 44.8 53.06
DMF 5.0 5.92
Ethanol 25.0 29.59
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 845.01 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Yao W, Xu G, Li D, Bai B, Wang H, Cheng H, Zheng J, Sun X, Lin Z, Deng Q, Yu Z. Staphylococcus aureus with an erm-mediated constitutive macrolide-lincosamide-streptogramin B resistance phenotype has reduced susceptibility to the new ketolide, solithromycin. BMC Infect Dis. 2019 Feb 19;19(1):175. doi: 10.1186/s12879-019-3779-8. PMID: 30782125; PMCID: PMC6381629. 2. Piccinelli G, Fernandes P, Bonfanti C, Caccuri F, Caruso A, De Francesco MA. In vitro activity of solithromycin against erythromycin-resistant Streptococcus agalactiae. Antimicrob Agents Chemother. 2014;58(3):1693-8. doi: 10.1128/AAC.02210-13. Epub 2013 Dec 30. Erratum in: Antimicrob Agents Chemother. 2018 Oct 24;62(11): PMID: 24379197; PMCID: PMC3957870. 3. Okusanya OO, Forrest A, Bhavnani SM, Fernandes P, Ambrose PG, Andes DR. Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e02606-18. doi: 10.1128/AAC.02606-18. PMID: 31182534; PMCID: PMC6658793. 4. Figueira M, Fernandes P, Pelton SI. Efficacy of Solithromycin (CEM-101) for Experimental Otitis Media Caused by Nontypeable Haemophilus influenzae and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5533-8. doi: 10.1128/AAC.00863-16. PMID: 27401563; PMCID: PMC4997842.
In vitro protocol:
1. Yao W, Xu G, Li D, Bai B, Wang H, Cheng H, Zheng J, Sun X, Lin Z, Deng Q, Yu Z. Staphylococcus aureus with an erm-mediated constitutive macrolide-lincosamide-streptogramin B resistance phenotype has reduced susceptibility to the new ketolide, solithromycin. BMC Infect Dis. 2019 Feb 19;19(1):175. doi: 10.1186/s12879-019-3779-8. PMID: 30782125; PMCID: PMC6381629. 2. Piccinelli G, Fernandes P, Bonfanti C, Caccuri F, Caruso A, De Francesco MA. In vitro activity of solithromycin against erythromycin-resistant Streptococcus agalactiae. Antimicrob Agents Chemother. 2014;58(3):1693-8. doi: 10.1128/AAC.02210-13. Epub 2013 Dec 30. Erratum in: Antimicrob Agents Chemother. 2018 Oct 24;62(11): PMID: 24379197; PMCID: PMC3957870.
In vivo protocol:
1. Okusanya OO, Forrest A, Bhavnani SM, Fernandes P, Ambrose PG, Andes DR. Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e02606-18. doi: 10.1128/AAC.02606-18. PMID: 31182534; PMCID: PMC6658793. 2. Figueira M, Fernandes P, Pelton SI. Efficacy of Solithromycin (CEM-101) for Experimental Otitis Media Caused by Nontypeable Haemophilus influenzae and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5533-8. doi: 10.1128/AAC.00863-16. PMID: 27401563; PMCID: PMC4997842.
1: McGhee P, Clark C, Kosowska-Shick KM, Nagai K, Dewasse B, Beachel L, Appelbaum PC. In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob Agents Chemother. 2010 Jan;54(1):230-8. doi: 10.1128/AAC.01123-09. Epub 2009 Nov 2. PMID: 19884376; PMCID: PMC2798494. 2: Putnam SD, Castanheira M, Moet GJ, Farrell DJ, Jones RN. CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram- positive and Gram-negative bacteria. Diagn Microbiol Infect Dis. 2010 Apr;66(4):393-401. doi: 10.1016/j.diagmicrobio.2009.10.013. PMID: 20022192. 3: Roblin PM, Kohlhoff SA, Parker C, Hammerschlag MR. In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. Antimicrob Agents Chemother. 2010 Mar;54(3):1358-9. doi: 10.1128/AAC.01343-09. Epub 2009 Dec 28. PMID: 20038627; PMCID: PMC2825974. 4: Jones RN, Ross JE, Rhomberg PR; Quality Control Working Group. MIC quality control guidelines and disk diffusion test optimization for CEM-101, a novel fluoroketolide. J Clin Microbiol. 2010 Apr;48(4):1470-3. doi: 10.1128/JCM.01992-09. Epub 2009 Dec 30. PMID: 20042620; PMCID: PMC2849615. 5: Woosley LN, Castanheira M, Jones RN. CEM-101 activity against Gram-positive organisms. Antimicrob Agents Chemother. 2010 May;54(5):2182-7. doi: 10.1128/AAC.01662-09. Epub 2010 Feb 22. PMID: 20176910; PMCID: PMC2863667. 6: Farrell DJ, Sader HS, Castanheira M, Biedenbach DJ, Rhomberg PR, Jones RN. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. Int J Antimicrob Agents. 2010 Jun;35(6):537-43. doi: 10.1016/j.ijantimicag.2010.01.026. Epub 2010 Mar 7. PMID: 20211548. 7: Biedenbach DJ, Castanheira M, Jones RN. Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection. Antimicrob Agents Chemother. 2010 Sep;54(9):4009-11. doi: 10.1128/AAC.01812-09. Epub 2010 Jul 12. PMID: 20625152; PMCID: PMC2934969. 8: Farrell DJ, Castanheira M, Sader HS, Jones RN. The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009). J Infect. 2010 Dec;61(6):476-83. doi: 10.1016/j.jinf.2010.08.010. Epub 2010 Sep 8. PMID: 20831882. 9: Llano-Sotelo B, Dunkle J, Klepacki D, Zhang W, Fernandes P, Cate JH, Mankin AS. Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob Agents Chemother. 2010 Dec;54(12):4961-70. doi: 10.1128/AAC.00860-10. Epub 2010 Sep 20. PMID: 20855725; PMCID: PMC2981243. 10: Bertrand D, Bertrand S, Neveu E, Fernandes P. Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors. Antimicrob Agents Chemother. 2010 Dec;54(12):5399-402. doi: 10.1128/AAC.00840-10. Epub 2010 Sep 20. PMID: 20855733; PMCID: PMC2981250. 11: Putnam SD, Sader HS, Farrell DJ, Biedenbach DJ, Castanheira M. Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci. Int J Antimicrob Agents. 2011 Jan;37(1):39-45. doi: 10.1016/j.ijantimicag.2010.08.021. PMID: 21075602. 12: Still JG, Schranz J, Degenhardt TP, Scott D, Fernandes P, Gutierrez MJ, Clark K. Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrob Agents Chemother. 2011 May;55(5):1997-2003. doi: 10.1128/AAC.01429-10. Epub 2011 Jan 31. PMID: 21282444; PMCID: PMC3088205. 13: Wittlin S, Ekland E, Craft JC, Lotharius J, Bathurst I, Fidock DA, Fernandes P. In vitro and in vivo activity of solithromycin (CEM-101) against Plasmodium species. Antimicrob Agents Chemother. 2012 Feb;56(2):703-7. doi: 10.1128/AAC.05039-11. Epub 2011 Nov 14. PMID: 22083475; PMCID: PMC3264280. 14: Sutcliffe JA. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci. 2011 Dec;1241:122-52. doi: 10.1111/j.1749-6632.2011.06323.x. PMID: 22191530. 15: Golparian D, Fernandes P, Ohnishi M, Jensen JS, Unemo M. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea? Antimicrob Agents Chemother. 2012 May;56(5):2739-42. doi: 10.1128/AAC.00036-12. Epub 2012 Feb 21. PMID: 22354296; PMCID: PMC3346660. 16: Bush K. Improving known classes of antibiotics: an optimistic approach for the future. Curr Opin Pharmacol. 2012 Oct;12(5):527-34. doi: 10.1016/j.coph.2012.06.003. Epub 2012 Jun 28. PMID: 22748801. 17: Rodvold KA, Gotfried MH, Still JG, Clark K, Fernandes P. Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects. Antimicrob Agents Chemother. 2012 Oct;56(10):5076-81. doi: 10.1128/AAC.00766-12. Epub 2012 Jul 16. PMID: 22802254; PMCID: PMC3457395. 18: Rodgers W, Frazier AD, Champney WS. Solithromycin inhibition of protein synthesis and ribosome biogenesis in Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae. Antimicrob Agents Chemother. 2013 Apr;57(4):1632-7. doi: 10.1128/AAC.02316-12. Epub 2013 Jan 14. PMID: 23318809; PMCID: PMC3623315. 19: Olsen B, Pham TL, Golparian D, Johansson E, Tran HK, Unemo M. Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from Vietnam, 2011. BMC Infect Dis. 2013 Jan 25;13:40. doi: 10.1186/1471-2334-13-40. PMID: 23351067; PMCID: PMC3574855. 20: Kobayashi Y, Wada H, Rossios C, Takagi D, Higaki M, Mikura S, Goto H, Barnes PJ, Ito K. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-κB inhibition. J Pharmacol Exp Ther. 2013 Apr;345(1):76-84. doi: 10.1124/jpet.112.200733. Epub 2013 Jan 28. PMID: 23359665.

View History

ARH-049020

ARH-049020

Cefmenoxime free base

Cefmenoxime free base

Argyrophilic acid

Argyrophilic acid

Cefoxazole

Cefoxazole